Lifestyle Features

Smart ring maker Oura eyes $15.6 billion IPO valuation in fall listings demand test

Manya Saini, Reuters  |  Updated Sept. 21 - 10:16 a.m.  |  Save Story

Oura kicked off the roadshow for its US initial public offering on Monday, targeting a fully-diluted valuation ​of $15.62 billion as the smart ring maker tests investor appetite for consumer technology companies after a tepid start to the fall IPO season.

J&J's Caplyta meets main goal of bipolar mania study

Reuters  |  Updated Sept. 21 - 7:23 a.m.  |  Save Story

Johnson & Johnson said on Monday its experimental use of Caplyta ​for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to ‌expanding beyond its currently approved uses.

Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients

Reuters  |  Updated Sept. 21 - 7:22 a.m.  |  Save Story

Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated ​average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly's rival drug.

'Momnesia' pregnancy forgetfulness linked to brain circuit disruption

Will Dunham, Reuters  |  Posted Sept. 21 - 4:03 a.m.  |  Save Story

It is sometimes called "momnesia," "mommy brain," "pregnancy brain" or "baby brain" — the forgetfulness, mental fogginess and cognitive changes that many women may experience during pregnancy. For instance, a woman might walk into the kitchen and ​forget why she did, or perhaps misplace her car keys in the bathroom.

Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion

Reuters  |  Updated Sept. 20 - 6:29 p.m.  |  Save Story

Australia's Telix Pharmaceuticals said on Monday it has agreed ​to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free ‌basis, further boosting its radiopharmaceutical ambitions.

HYROX brings 16,000 competitors to Salt Lake City

VideoDebbie Worthen, KSL  |  Posted Sept. 19 - 1:05 p.m.  |  Save Story

About 16,000 athletes competed at the Salt Palace Convention Center in Salt Lake City in a HYROX competition.

Jana urges Cooper to replace CEO, explore asset sales after performance setbacks

Reuters  |  Updated Sept. 18 - 11:10 a.m.  |  Save Story

Activist investor Jana Partners on Friday urged Cooper Companies to launch ​an external search for a new CEO and consider asset sales, arguing recent missteps have hurt investor confidence ‌and weighed on the medical device maker's market value.

US pharmacy chain Walgreens plans tech centre in India's Chennai, expected to create 250 jobs

Reuters  |  Posted Sept. 18 - 1:53 a.m.  |  Save Story

US-based pharmacy chain Walgreens ​plans to establish a new Global Capability Centre (GCC) ‌in Chennai, the capital of the ⁠southern Indian ​state of ⁠Tamil Nadu.

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

Reuters  |  Updated Sept. 17 - 9:55 p.m.  |  Save Story

Dr Reddy's Laboratories said on ​Friday it had signed an agreement with Japanese drugmaker Takeda Pharmaceutical ‌to promote and distribute the Qdenga dengue ⁠vaccine in India.

SPONSORED

This year's AARP Andrus Award recipient finds purpose through music and community

VideoTamara Vaifanua, KSL  |  Updated Sept. 17 - 4:35 p.m.  |  Save Story

Alice Cipollini, 80, shows how a life of service has no age limit.

Virbac confirms outlook as Supercharge platforms drive profit growth

Reuters  |  Updated Sept. 17 - 10:37 a.m.  |  Save Story

French animal health company Virbac reported higher ​half-year core profit on Thursday with a recurring operating profit, excluding amortization of ‌assets due to acquisitions, rising 6.8% to 144.2 million euros ($165.50 ⁠million), compared with 135.0 ​million euros a ⁠year earlier.

Advent to invest $328.5 million in India's Yatharth Hospital for 24.9% stake

Reuters  |  Updated Sept. 17 - 9:10 a.m.  |  Save Story

U.S.-based private equity firm Advent International ​said on Thursday it will invest 31.5 billion rupees ($328.53 million) in Yatharth ‌Hospital for a 24.9% stake, sending shares of the ⁠Indian hospital operator ​to a record ⁠high.

Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

Siddhi Mahatole, Reuters  |  Updated Sept. 17 - 9:05 a.m.  |  Save Story

Orbis Medicines said on Thursday it had signed a drug ​discovery and licensing agreement worth up to $1.4 billion with Novo Nordisk to develop oral therapies for cardiometabolic diseases, traditionally treated ‌with injectable drugs.

Healthcare firm Ramsay Generale de Sante sees 2027 revenue rising by up to 3%

Reuters  |  Posted Sept. 17 - 12:27 a.m.  |  Save Story

French healthcare ​provider Ramsay Generale de Sante ‌expects its revenue to ⁠grow ​by 2% ⁠to 3% ‌in 2027, ‌with a stable ⁠core ⁠profit margin compared to 2026, it said ahead of its capital ‌markets day ​on Thursday.

Novartis halts ALS drug development after mid-stage trial failure

Sriparna Roy, Reuters  |  Updated Sept. 16 - 2:31 p.m.  |  Save Story

Novartis has halted development of an experimental drug for amyotrophic ​lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this ‌year.

Ebola response making progress in Congo, but outbreak 'far from over,' WHO says

Siddhi Mahatole, Reuters  |  Updated Sept. 16 - 8:47 a.m.  |  Save Story

The World Health Organization said on Wednesday there were encouraging signs ​measures to contain an Ebola epidemic in Democratic Republic of Congo were gaining ground, though it warned the outbreak was "far from ‌over."

Sling Therapeutics raises $123 million to advance thyroid eye disease drug

Kunal Das and Siddhi Mahatole, Reuters  |  Updated Sept. 16 - 8:10 a.m.  |  Save Story

Drug developer Sling Therapeutics said on ​Wednesday it had raised $123 million to advance a late-stage trial of its experimental oral drug to treat thyroid eye ‌disease.

Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs

Richa Naidu, Reuters  |  Updated Sept. 16 - 8:03 a.m.  |  Save Story

Consumer health company Haleon has achieved growing sales of ​products to counter side-effects of weight-loss drugs in the United States, the company said, capitalising on the rising popularity ‌of GLP-1 medication.

ByteDance completes $290 million fundraising for AI drug unit after its spin-off, sources say

Kane Wu, Reuters  |  Updated Sept. 16 - 8:03 a.m.  |  Save Story

Chinese social media and internet company ByteDance has ​completed a $290 million fundraising for its AI drugmaking unit after spinning it off from the group, two people with ‌knowledge of the matter said on Wednesday.